NP / PA
Shadeland Anesthesia & Pain Associates INC.
Shadeland Anesthesia & Pain Associates INC. was paid $7.12M by Medicaid between Jan 2018 and Dec 2024, across 50 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 60% of everything it billed.
33Billing provider infoSHADELAND ANESTHESIA & PAIN ASSOCIATES INC.
INDIANAPOLIS, IN 46260
INDIANAPOLIS, IN 46260
33aNPI1477589000assigned 06/24/2006
33bProvider typeNurse Practitioner
28Total paid$7.12M
24GClaims218,212
24DCodes billed50
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Nurse Practitioner providers in Indiana
Rank by total paid#4 of 95
Median peer was paid$52K
This provider vs. median137×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,295 | $151K | |
| 2019 | 21,188 | $222K | |
| 2020 | 22,758 | $415K | |
| 2021 | 27,273 | $727K | |
| 2022 | 30,420 | $1.13M | |
| 2023 | 51,966 | $2.15M | |
| 2024incomplete | 44,312 | $2.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 60% | 118,643 | 92,834 | $4.28M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 25,744 | 22,488 | $949K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 9.0% | 16,660 | 14,218 | $639K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.7% | 21,746 | 16,583 | $407K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.5% | 2,107 | 1,893 | $178K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 2.4% | 13,716 | 11,009 | $172K |
| 99205 | Prolong outpt/office vis | 1.7% | 1,568 | 1,260 | $121K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.1% | 1,107 | 907 | $80K |
| 64483 | 1.0% | 685 | 541 | $73K | |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 505 | 474 | $36K |
| 99152 | <1% | 6,030 | 4,288 | $33K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,190 | 516 | $31K |
38 more codes
| 90834 | Psychotherapy session, about 45 minutes | <1% | 701 | $30K |
| 62370 | <1% | 588 | $18K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 619 | $11K |
| 64484 | <1% | 202 | $11K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 194 | $7K |
| 62323 | <1% | 169 | $6K | |
| 64493 | <1% | 113 | $6K | |
| 20610 | <1% | 224 | $5K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 301 | $3K |
| 64494 | <1% | 100 | $3K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 491 | $2K |
| 64635 | <1% | 15 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 236 | $1K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 246 | $1K |
| 76942 | <1% | 55 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 180 | $874.94 |
| 64636 | <1% | 15 | $853.67 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 33 | $782.47 |
| 97162 | <1% | 16 | $771.76 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 179 | $765.71 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 60 | $714.24 |
| 72141 | <1% | 15 | $544.56 | |
| 62321 | <1% | 12 | $430.65 | |
| 62368 | <1% | 19 | $359.33 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 407 | $272.92 |
| 96130 | <1% | 12 | $258.98 | |
| 96131 | <1% | 12 | $191.30 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 191 | $99.21 |
| 96138 | <1% | 12 | $82.87 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 30 | $73.54 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 92 | $59.84 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 15 | $51.62 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 89 | $0.34 |
| 4004F | 0% | 150 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 2,331 | $0.00 |
| 1125F | 0% | 188 | $0.00 | |
| 3008F | 0% | 156 | $0.00 | |
| 99406 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOWLOWITZ, EDWARD (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Integrated Pain Solutions Incorporated | Columbus, OH | $2.14M |
| Indiana Pain Centers-Evansville LLC | Evansville, IN | $224K |
| Center for Special Surgery LLC | Indianapolis, IN | $120K |
| Lafayette Surgery Center LLC | Lafayette, IN | $19K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.